Frank S. Lieberman

12.4k total citations
139 papers, 5.0k citations indexed

About

Frank S. Lieberman is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frank S. Lieberman has authored 139 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Genetics, 43 papers in Oncology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frank S. Lieberman's work include Glioma Diagnosis and Treatment (95 papers), Brain Metastases and Treatment (26 papers) and Radiomics and Machine Learning in Medical Imaging (18 papers). Frank S. Lieberman is often cited by papers focused on Glioma Diagnosis and Treatment (95 papers), Brain Metastases and Treatment (26 papers) and Radiomics and Machine Learning in Medical Imaging (18 papers). Frank S. Lieberman collaborates with scholars based in United States, Canada and France. Frank S. Lieberman's co-authors include Patrick Y. Wen, Michael D. Prados, Kathleen R. Lamborn, Timothy F. Cloughesy, Mark R. Gilbert, Minesh P. Mehta, Lisa M. DeAngelis, John G. Kuhn, James M. Mountz and H. Ian Robins and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Frank S. Lieberman

138 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank S. Lieberman United States	38	2.5k	1.6k	1.5k	931	854	139	5.0k
Nicholas Butowski United States	41	3.5k 1.4×	1.4k 0.9×	2.0k 1.3×	1.3k 1.4×	1.1k 1.3×	188	6.3k
David M. Peereboom United States	39	2.2k 0.9×	1.7k 1.1×	1.3k 0.8×	1.7k 1.8×	615 0.7×	198	4.8k
Xiaobu Ye United States	39	2.3k 0.9×	2.6k 1.7×	1.3k 0.9×	1.4k 1.5×	1.2k 1.5×	151	6.8k
Mustafa Khasraw Australia	34	1.9k 0.8×	2.3k 1.5×	1.7k 1.2×	1.5k 1.6×	956 1.1×	194	5.8k
Katherine B. Peters United States	35	2.3k 0.9×	1.1k 0.7×	1.3k 0.9×	1.1k 1.2×	373 0.4×	230	4.6k
Yoshitaka Narita Japan	37	2.6k 1.0×	1.3k 0.8×	2.0k 1.4×	1.2k 1.3×	375 0.4×	234	5.6k
Mathilde C.M. Kouwenhoven Netherlands	33	3.1k 1.2×	793 0.5×	1.7k 1.2×	1.3k 1.4×	660 0.8×	99	5.2k
Jennifer Clarke United States	42	2.5k 1.0×	1.4k 0.9×	1.2k 0.8×	1.8k 1.9×	482 0.6×	175	5.7k
Weishi Yuan United States	13	2.9k 1.1×	1.3k 0.8×	2.6k 1.8×	975 1.0×	583 0.7×	20	6.3k
Ghazaleh Tabatabai Germany	38	2.7k 1.1×	836 0.5×	1.9k 1.3×	926 1.0×	628 0.7×	183	5.3k

Countries citing papers authored by Frank S. Lieberman

Since Specialization

Citations

This map shows the geographic impact of Frank S. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank S. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank S. Lieberman more than expected).

Fields of papers citing papers by Frank S. Lieberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank S. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank S. Lieberman. The network helps show where Frank S. Lieberman may publish in the future.

Co-authorship network of co-authors of Frank S. Lieberman

This figure shows the co-authorship network connecting the top 25 collaborators of Frank S. Lieberman. A scholar is included among the top collaborators of Frank S. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank S. Lieberman. Frank S. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Drappatz, Jan, et al.. (2023). Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.. Journal of Clinical Oncology. 41(16_suppl). e14020–e14020. 1 indexed citations

Pilat, Mary Jo, Derek Shyr, Yu Shyr, et al.. (2023). Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer Research Communications. 3(2). 192–201. 18 indexed citations

Strowd, Roy E., Benjamin M. Ellingson, Catalina Raymond, et al.. (2023). Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. Journal of Neuro-Oncology. 165(1). 101–112. 17 indexed citations

Drappatz, Jan, et al.. (2023). Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme. Journal of Neuro-Oncology. 164(1). 179–190. 8 indexed citations

Gilbert, Mark R., Ying Yuan, Jimin Wu, et al.. (2020). A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-Oncology. 23(3). 468–477. 37 indexed citations

Aziz, Yasmin, Laurie E. Knepper, Frank S. Lieberman, et al.. (2020). Brainstem Anaplastic Astrocytoma, IDH-Mutant, WHO Grade III Presenting with Multiple Cranial Nerve Palsies and Diffuse Neuroaxis Leptomeningeal Involvement (4885). Neurology. 94(15_supplement). 1 indexed citations

Drappatz, Jan & Frank S. Lieberman. (2018). Chemotherapy of Oligodendrogliomas. Progress in neurological surgery. 31. 152–161. 2 indexed citations

Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology. 36(15_suppl). 2058–2058. 12 indexed citations

Nayak, Lakshmi, John de Groot, Jeffrey S. Wefel, et al.. (2017). Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology. 132(1). 181–188. 23 indexed citations

10.

Okada, Hideho, Lisa H. Butterfield, Ronald L. Hamilton, et al.. (2014). Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. Clinical Cancer Research. 21(2). 286–294. 83 indexed citations

11.

Oborski, Matthew J., et al.. (2014). Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10. Translational Oncology. 7(1). 111–119. 15 indexed citations

12.

Groot, John de, Kathleen R. Lamborn, Susan M. Chang, et al.. (2011). Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology. 29(19). 2689–2695. 168 indexed citations

13.

Iwamoto, Fábio M., Kathleen R. Lamborn, John G. Kuhn, et al.. (2011). A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-Oncology. 13(5). 509–516. 94 indexed citations

14.

Park, Kyung-Jae, Hideyuki Kano, Aditya Iyer, et al.. (2011). Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study. Journal of Neuro-Oncology. 107(2). 323–333. 77 indexed citations

15.

Okada, Hideo, Paweł Kaliński, Arlan Mintz, et al.. (2011). Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma.. Journal of Clinical Oncology. 29(15_suppl). 2506–2506. 1 indexed citations

16.

Hu, Bo, Kun-Wei Liu, Haizhong Feng, et al.. (2010). ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain. Molecular Cancer Therapeutics. 9(4). 929–941. 26 indexed citations

17.

Gilbert, Mark R., John G. Kuhn, Kathleen R. Lamborn, et al.. (2009). Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05–02). Journal of Clinical Oncology. 27(15_suppl). 2005–2005. 33 indexed citations

18.

Marsh, Gary M., Jeanine M. Buchanich, Ada O. Youk, et al.. (2008). Long-term Health Experience of Jet Engine Manufacturing Workers: II. Total and Cause-Specific Mortality Excluding Central Nervous System Neoplasms. Journal of Occupational and Environmental Medicine. 50(10). 1117–1129. 8 indexed citations

19.

Hausheer, Frederick H., Richard L. Schilsky, Stacey Bain, Elmer Berghorn, & Frank S. Lieberman. (2006). Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology. 33(1). 15–49. 307 indexed citations

20.

Lassman, Andrew B., Michael R. Rossi, Lauren E. Abrey, et al.. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research. 11(21). 7841–7850. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact